Meeting
2017 ASCO Annual Meeting
Asymptomatic distant recurrence detection and survival in early stage breast cancer: A nationally representative study.
Authors
Jessica R. Schumacher
Department of Surgery, University of Wisconsin, Madison, WI
Jessica R. Schumacher , Heather B. Neuman , Ying Zhang , Menggang Yu , David J. Vanness , Yajuan Si , Elizabeth S Burnside , Kathryn Jean Ruddy , Ann H. Partridge , Deborah Schrag , Stephen B. Edge , Elizabeth A Jacobs , Jeffrey Havlena , Amanda B. Francescatti , Patricia Spears , David P Winchester , Daniel P. McKellar , George J. Chang , Benjamin D. Kozower , Caprice Christian Greenberg
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Health Services Research, Clinical Informatics, and Quality of Care
Track
Quality Care/Health Services Research
Sub Track
Outcomes
Citation
J Clin Oncol 35, 2017 (suppl; abstr 6520)
DOI
10.1200/JCO.2017.35.15_suppl.6520
Abstract #
6520
Poster Bd #
342
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
A phase III randomized trial of metformin versus placebo on recurrence and survival in early stage breast cancer (BC) (NCIC Clinical Trials Group MA.32).
First Author: W. Parulekar
Poster
2023 ASCO Annual Meeting
Oral paclitaxel and dostarlimab with or without trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant ISPY 2 TRIAL.
First Author: Rebecca Arielle Shatsky
Poster
2023 ASCO Annual Meeting
Oral paclitaxel, carboplatin, and dostarlimab (OPE/Cb/D) without and with trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL.
First Author: Kay T Yeung
Poster
2023 ASCO Annual Meeting
An analysis of breast cancer index scores predicting benefit of extended endocrine therapy by race.
First Author: Nicholas Siu-Li